Presented today at #ERA2026, the INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death.
Explore the research: spkl.io/633287Badg
